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Tso-Fu Wang,1,2,3 He Huang,4 Cheng-Hwai Tzeng,5 Po-Nan Wang,6 Tong Wu,7 Jing Sun,8
Jih-Luh Tang,9 Jiong Hu,10 Sheng-Fung Lin,11,12 Ruey-Ho Kao1,2We retrospectively analyzed the impact of donor characteristics and HLA matching on outcomes in Chinese
patients undergoing unrelated hematopoietic stem cell transplantation (HSCT). A total of 693 patients with
hematologic malignancies who underwent HSCT between 2005 and 2010 had available survival data at 100
days or 1 year posttransplantation in the Buddhist Tzu-Chi Stem Cell Center database. The overall survival
rates at 100 days and 1 year were 83.3% and 65.2%, respectively. Mismatches of HLA-A, -B, and -DRB1 at the
antigen or allele level, along with inadequate cell dose, were associated with a significant risk of mortality
(hazard ratio [HR] 5 2.36, P\.001; HR 5 1.44, P 5 .005; and HR 5 2.20, P 5 .009, respectively). In 107
donors with matched HLA-A, -B and -DRB1 and known HLA-C match status, 22.4% had an HLA-C antigen
mismatch, resulting in an HR of 2.87 for mortality relative to complete 8/8 matches (P 5 .005). Recipients
with unknown HLA-C match status also had a significantly worse outcome (HR5 1.73; P5 .039). Multivar-
iate analysis revealed that cell dose and HLA-A, -B, -C, and -DRB1 antigen match status significantly affected
the final outcome of survival (P5 .012 and\.001, respectively). Our data indicate that HLA-C match status
should be confirmed before HSCT from an unrelated donor. Inadequate cell dose remains an important de-
terminant of poor transplantation survival. Further studies to elucidate the importance of matching of spe-
cific HLA loci are needed to better understand the risk of HSCTand improve patient outcomes.
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Hematopoietic stem cell transplantation (HSCT)
has been successfully applied to treat numerous malig-
nant and nonmalignant hematologic diseases. The use
of stem cells from HLA-matched unrelated volunteer
donors (MUDs) is an accepted option for patients
without a matching sibling donor, with comparable
outcomes to matched sibling donor HSCT [1]. In Tai-
wan, MUDs account for approximately 25% of graft
sources, and this percentage is increasing [2]. Although1Department of Hematology and Oncology, Tzu-Chi
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The importance of HLA matching is well docu-
mented in unrelated donor HSCT [3-7]. Donor regis-
try searches often identify multiple HLA-A, -B,
and -DRB1 matched donors for a patient [8].Institute of Hematology, Rui Jin Hospital affiliated to Shanghai
Jiao Tong University School of Medicine, Shanghai, China;
11Division of Hematology and Oncology, Department of
Internal Medicine, Kaohsiung Medical University Hospital,
Kaohsiung, Taiwan; and 12Faculty of Medicine, College of
Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Financial disclosure: See Acknowledgments on page 1943.
Correspondence and reprint requests: Dr. Ruey-Ho Kao, Depart-
ment of Hematology and Oncology, Tzu-Chi General Hos-
pital, 707 Section 3, Chung Yang Road, Hualien 970, Taiwan
(e-mail: rueyhokao@tzuchi.com.tw).
Received June 20, 2012; accepted July 24, 2012
 2012 American Society for Blood and Marrow Transplantation
1083-8791/$36.00
http://dx.doi.org/10.1016/j.bbmt.2012.07.015
Table 1. Patient Disease Summary Statistics
Disease (n 5 693) n (%)
Acute myelogenous leukemia 247 (35.6%)
Acute lymphoblastic leukemia 210 (30.3%)
Acute biphenotypic/nonspecific leukemia 13 (1.9%)
Chronic myelogenous leukemia 132 (19%)
Myelodysplastic syndrome 42 (6.1%)
Non-Hodgkin lymphoma 34 (4.9%)
Hodgkin’s lymphoma 7 (1.0%)
Multiple myeloma 2 (0.3%)
Chronic lymphocytic leukemia 5 (0.7%)
Other hematologic malignancy 1 (0.1%)
1940 Biol Blood Marrow Transplant 18:1935-1944, 2012T.-F. Wang et al.Strategies for optimal unrelated donor selection vary.
Transplant physicians often prefer donors who are
HLA-C–matched, male, younger than other possible
donors, seronegative for cytomegalovirus (CMV),
andABO-compatible [9-12]. Priority alsomay be given
to female donors who are nulliparous [13] and donors
who are racially matched with the patient. Most of
these conclusions were derived from studies using
data fromWestern patients. To date, no systemic anal-
ysis has been conducted regarding the effects of donor
factors on the outcomes ofMUDHSCT inChinese in-
dividuals. A study of the effects of donor characteristics
and HLA matching on transplantation outcomes in
a Chinese population may lead to improved outcomes
of MUD HSCT in the future.
In the present study, we examined the effects of var-
ious donor characteristics and HLA matching on out-
comes in Chinese recipients of MUD allogeneic
HSCT, focusing on the need for and impact of HLA-C
matching.We analyzed the associations between overall
survival and donor factors including age, ABO compati-
bility, sex, stem cell source, stem cell dose, and HLA
matching in the patient–donor pairs recorded in the
database of the Buddhist Tzu-Chi Stem Cell Center.PATIENTS AND METHODS
We analyzed data from MUD HSCTs performed
in Taiwan and China between January 2005 and
December 2010 under the auspices of the Buddhist
Tzu-Chi Stem Cell Center. All identifying donor and
recipient information was removed before analysis.
This study was approved by the Institutional Review
Board of Tzu-Chi General Hospital. Patients with
nonmalignant diseases were excluded from the study.
A total of 790 donor–recipient pairs were available for
100-day and 1-year survival analysis, 693 of whom
underwent HSCT for treatment of a hematologic
malignancy. The patients received a variety of pre-
transplantation conditioning and GVHD prophylaxis
regimens, with much of this information not available
in the current dataset.
Various HLA typing methods were applied in
different institutes; however, all of the donors and
many of the recipients underwent molecular-basedHLA typing at the Buddhist Tzu-Chi Stem Cell Cen-
ter. Donors and recipients were considered allele-
matched for a given locus when their high-resolution
typing results were identical. Antigen-level disparity
involved conversion of the 4-digit typing result back
to its first 2 digits, with the exception of a few
HLA-B alleles that were mapped to their correspond-
ing serologic specificities.
The planned volume of harvested bone marrow
(BM) was 20mL/kg recipient body weight, with amin-
imal volume of 600 mL and a maximum volume of
20 mL/kg donor weight [14]. The target CD341 cell
dose for mobilized peripheral blood stem cells
(PBSCs) was 5  106 cells/kg recipient body weight.
If the target CD341 cell dose was not met with the first
apheresis, a second apheresis procedure was performed
[15]. A cell dose inadequate for transplantation was de-
fined as a total nucleated cell count\2  108 cells/kg
recipient weight for harvested BM or a CD341 cell
count\2  106/kg for mobilized PBSCs.
ABO-matched pairs had identical ABO blood
groups. Major ABO mismatches were defined as the
presence of antidonor isohemagglutinins in recipients,
that is, transplantation from a non–type O donor to
a type O recipient or from a type AB donor to a type A
or B recipient. Minor ABO mismatches included the
presence of antirecipient isohemagglutinins in donors,
that is, transplantation from a type O donor to a non–
type O recipient or from a type A or B donor to an
type AB recipient. In the bidirectional mismatched
group, both patients and donors had isoagglutinins
directed against each other, that is, transplantation
from a type A donor to a type B recipient or vice versa.
Characteristics of recipients and donors were
described by summary statistics. Survival rates were cal-
culated using the Kaplan-Meier method and compared
using the log-rank test.Donor factors analyzed included
age, sex,HLAmatching, blood typematching, and stem
cell dose. A Cox proportional hazards model was used
formultivariate analysis of the effects of these donor fac-
tors and HLA matching on survival outcome. A P value
\.05 was considered statistically significant. All tests
were performed using MedCalc for Windows, version
9.6.0.0 (MedCalc Software, Mariakerke, Belgium).RESULTS
In the 693 HSCT recipients with hematologic
malignancies, the most common indications for trans-
plantation were acute myelogenous leukemia (35.6%),
acute lymphoblastic leukemia (30.3%), and chronic
myelogenous leukemia (19.0%). Other indications are
listed in Table 1. Median age was 26 years (range, 1-69
years) for the recipients and 30 years (range, 19-54 years)
for the donors. Details of disease status were known for
236 recipients (34.1%) before transplantation, and 36
recipients (15.3%) were beyond second complete
Table 2. Log-Rank Test of the Effect of Donor Characteristics and HLA Matching on Overall Survival after Unrelated HSCT
HR 95% Cl P
Antigen matching for 6 loci
Match at HLA-A, -B, and -DRB1 (n 5 626) 1
Any mismatch at HLA-A, -B, or -DRB1 (n 5 67) 2.36 2.11-5.71 <.001
Antigen matching for 8 loci
Match at HLA-A, -B, -C, and -DRB1 (n 5 83) 1
Match at HLA-A, -B, and -DRB1 but unknown HLA-C status (n 5 519) 1.73 1.02-2.40 .039
Match at HLA-A, -B, and -DRB1 but mismatch at HLA-C (n 5 24) 2.87 1.50-10.15 .005
Any mismatch at HLA-A, -B, or -DRB1 (n 5 67) 3.90 2.28-7.11 <.001
Allele matching for 6 loci
Match at HLA-A, -B, and -DRB1 (n 5 406) 1
Any mismatch at HLA-A, -B, or -DRB1 (n 5 282) 1.45 1.12-1.91 .005
Allele matching for 8 loci
Match at HLA-A, -B, -C, and -DRB1 (n 5 61) 1
Match at HLA-A, -B, and -DRB1 but unknown HLA-C status (n 5 329) 1.53 0.87-2.41 .158
Match at HLA-A, -B, and -DRB1 but mismatch at HLA-C (n 5 16) 1.18 0.36-3.87 .779
Any mismatch at HLA-A, -B, or -DRB1 (n 5 282) 2.11 1.14-2.84 .012
Cell dose
Adequate (n 5 675) 1
Inadequate (n 5 18) 2.20 1.34-7.75 .009
Source
BM (n 5 189) 1
PBSCs (n 5 504) 0.96 0.72-1.28 .792
Blood type
ABO match (n 5 269) 1
Major ABO mismatch (n 5 147)* 1.16 0.82-1.66 .398
Minor ABO mismatch (n 5 203)† 1.05 0.76-1.44 .785
Bidirectional ABO mismatches (n 5 61)‡ 0.90 0.56-1.47 .686
Sex matching
Female to female (n 5 111) 1
Male to male (n 5 281) 1.31 0.88-1.88 .193
Male to female (n 5 156) 1.25 0.80-1.93 .325
Female to male (n 5 145) 1.32 0.85-2.03 .218
Donor age, years
19-29 (n 5 326) 1
30-39 (n 5 268) 1.09 0.82-1.45 .541
40-54 (n 5 99) 1.31 0.90-2.00 .149
*Transplantation from a non–type O donor to a type O recipient or from a type AB donor to a type A or B recipient.
†Transplantation from a type O donor to a non–type O recipient or from a type A or B donor to a type AB recipient.
‡Transplantation from a type A donor to a type B recipient or vice versa.
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conditioning regimen were available for 203 recipients,
185 ofwhom (91.1%) received amyeloablative regimen.
Allele typing data were unavailable for 5 recipients,
and blood type data were unavailable for another
13 recipients.
A total of 107 HLA-A, -B, and -DRB1 antigen-
matched donor–patient pairs had known HLA-C
matching status; 24 (22.4%) were not matched at
HLA-C. Fifteen of 76 donor–patient pairs (19.7%)
who were matched at the HLA-A, -B, and -DRB1
allele level were mismatched at HLA-C. The median
CD341 cell dose was 7.41  106 cells/kg for PBSC
transplantation, and the median total nucleated cell
count was 4.24  108 cells/kg for BM transplantation.
Two of 189 BM transplants (1.1%) and 16 of 504
PBSC transplants (3.2%) met the criteria for an inad-
equate cell dose for transplantation.
The overall 100-day and 1-year survival rates were
83.3% and 65.2%, respectively. The log-rank test for
the effect of donor characteristics on recipient survival
times revealed a significant risk of mortality in recipi-
ents with any antigen or allele mismatch of HLA-A, -B,or -DRB1 (hazard ratio [HR] 5 2.36, P \ .001 and
HR5 1.44, P5 .005, respectively) (Table 2; Figure 1A
and B). When the analysis incorporated the influence
of HLA-C, recipients antigen-matched at HLA-A, -B,
and -DRB1 but antigen-mismatched at HLA-C had
an HR of 2.87 relative to those with a complete 8 of 8
match (P5 .005) (Figure1C).UnknownHLA-Cantigen
match status was also associated with a significant risk of
mortality (HR 5 1.73; P 5 .039). The HR was highest
for any antigen mismatch at HLA-A, -B, or -DRB1
compared with an 8/8 match (HR 5 3.9; P\ .001). At
the allele level, statistically significant differences in
risk were observed between any mismatch at the
HLA-A, -B, or -DRB1 locus relative to a complete 8/8
match (HR 5 2.11; P 5 .012) (Figure 1D). This risk
trend remained for HLA-C allele matching status,
although it was not statistically significant.
Patients who received cell doses inadequate for
transplantation had worse survival compared with
those who received adequate cell doses (HR 5 2.20;
P 5 .009). Stem cell source, donor age, sex match,
and blood type match did not affect overall survival
rates (Table 2). Multivariate analysis using a Cox
Figure 1. Overall survival rates according to HLAmatching status. (A) Survival as an outcome for antigenmatching at HLA-A, -B, or -DRB1. (B) Survival
as an outcome for allele matching at HLA-A, -B, or -DRB1. (C) Influence of the presence of HLA-C matching, in addition to matching at HLA-A, -B, and
-DRB1, at the antigen level. (D) The influence of the presence of HLA-C matching, in addition to matching at HLA-A, -B, and -DRB1, at the allele level.
1942 Biol Blood Marrow Transplant 18:1935-1944, 2012T.-F. Wang et al.proportional hazards regression model showed that
cell dose and HLA-A, -B, -C, and -DRB1 antigen
matching status significantly affected the final out-
come of survival (P 5 .012 and\.001, respectively).DISCUSSION
Although several previous large cohort studies
have focused on the influence of donor factors and
HLA matching on the outcome of unrelated HSCT,
most of these data were derived fromWestern and Jap-
anese populations. Here we describe for the first time
the effects of donor factors and HLA matching status
on outcomes in recipients ofMUDHSCT in aChinese
population. Our results demonstrate the significant
impact of HLA-A, -B, or -DRB1 mismatches at the
antigen and allele levels on transplantation outcomes.
Previous studies have shown that mismatches at
HLA-A or -DRB1 appeared to have a greater negative
impact on survival compared with mismatches at
HLA-Bor -C [6,7]. Japanese studies reported no signif-
icant negative impact of HLA-C mismatch on overall
survival [3,5]. These findings suggest that the impact
of HLA-C onHSCT outcome may vary among differ-ent races. Most of the previous studies primarily evalu-
ated HSCTs with BM as the stem cell source [4-7]. In
the current National Marrow Donor Program files,
.70% of adult donations are PBSCs [16]. A recent
analysis of PBSC transplantation found that HLA-C
antigen-level mismatch is more detrimental to survival
[17]. This finding raises the possibility of a differential
effect of HLA-C match on the outcomes of BM and
PBSC transplantation. Given that PBSC transplants
represented 72.7% of all HSCTs analyzed in the pres-
ent study, we also observed a significant adverse effect
of HLA-C match on survival outcome. This discor-
dance of the impact of specific HLA matching among
different stem cell sources and among different ethnic
groups warrants further study.
Although our cohort was not large enough to allow
us to analyze the effect of mismatches at each specific
locus, our findings show a significant risk of mortality
related to HLA-C antigen mismatch in short-term
follow-up. The survival of HSCT recipients with
HLA-C antigen mismatch was similar to recipients
with anyHLA-A, -B, or -DRB1mismatch. In addition,
ensuring that donor–recipient pairs match at HLA-A,
-B, and -DRB1 while ignoring HLA-C status might
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HSCT. Outcomes were significantly worse in recipi-
ents with unknown HLA-C status compared with
HLA-C–matched recipients. HLA-C antigen mis-
match was detected in 22.4% of recipient–donor pairs
with matched HLA-A, -B, and -DRB1, even though
the individuals were of the same ethnicity. These
HLA-C mismatches were not related to linkage
disequilibrium due to allelic mismatches at HLA-B;
the percentage of HLA-C mismatches was similar in
donor–recipient pairs with allele-matched HLA-A,
-B, and -DRB1. The actual incidence of mismatch
might be higher, given that some physicians may avoid
HSCT after confirming an HLA-C mismatch. The
observed survival trend remained with regard to allele
matching status, although the power of these findings
is limited by the small number of cases in the sub-
groups. Our findings suggest that determination of
HLA-C status (at least at the antigen level) is critical
to understanding the risk of MUD HSCT.
A recent study reported that 56% of patients will
have $10 suitably HLA-matched adult donors in the
currentNationalMarrowDonor Program files [18]. Al-
thoughsomedonorcharacteristicshavebeen recognized
aspotential risk factors for transplantationoutcome, sev-
eral recent studies found no significant effects of donor
factors on the survival of HSCT recipients, with the ex-
ception of donor age [9,19,20]. In the present study, no
statistical differences in survivalwere associatedwithdo-
nor factors. This finding might reflect the relatively
small impact of donor factors, such as age, sex, and
ABOblood typematching, in contrast to the importance
of HLA matching and stem cell dose.
Previous evidence has demonstrated that the cell
dose is adversely correlated with transplantation out-
come [21-24]. Although inadequate cell dose has been
defined as\2  108 nucleated cells in BM grafts and
\2  106 CD341 cells in mobilized PBSC grafts, the
accurate incidence of inadequate cell dose and the ac-
tual risk associatedwith this factor are seldom reported.
In previous studies, a significant percentage (27%-
50%) of recipients received a relatively low BM cell
dose (2.4-2.6  108 cells/kg) [22,23], and approxi-
mately 18% of PBSC samples were found to have
poor mobilization (\20  106 CD341 cells/L) [25].
In the present study, 18 recipients (2.6%) had an inad-
equate cell dose (3.2% of PBSC donors and 1.1% of
BM donors). The incidence of poor mobilizers in our
study was comparable to that in a recent report of
PBSC harvesting [26]. Despite the efforts of donor
centers, procuring adequate cell doses remains a chal-
lenge in BM and PBSC collection. In the present study,
survival HRwas 2.20 (95%CI, 1.3-7.8; P5 .009) in re-
cipients with an inadequate cell dose. The possibility of
inadequate cell dose and the associated risk for trans-
plantation outcome should be incorporated into
pretransplantation considerations. Our recent worksuggests that some donor factors, including sex,
higher body weight/body mass index, high preharvest
WBC count, and younger age, might affect stem cell
collection from different sources [15,27]. If concerns
are raised about obtaining an adequate number of
stem cells, then further consideration of donor charac-
teristics might be helpful in selecting optimal donors,
even though the donor characteristics do not directly
affect transplantation outcome.
The major limitation of this study is insufficient
data for recipients. Only 34.1% of the recipients had
detailed information on disease status before trans-
plantation. In addition, data on conditioning regimens
and GVHD prophylaxis were unavailable for many
recipients, and data on CMV status were not available
in our database. Thus, we focused on the impact of
donor factors in recent transplantation for hematologic
malignancies between 2005 and 2010, to decrease the
confounding effects of disease and treatment differ-
ences among individuals. For patients in the first or sec-
ond complete remission, any antigenmismatch and any
allele mismatch atHLA-A, -B, or -DRB1were still sig-
nificantly associatedwith poor outcome (Supplemental
Table). Owing to our small number of patients, the im-
pact of HLA-C status and inadequate cell dose did not
reach significance in this subgroup analysis.
The primary mission of the Tzu-Chi Stem Cell
Center (also known as the Tzu-Chi Marrow Donor
Registry) is to provide a suitable donor for every
patient in need of transplantation, and to ensure that
stem cells are collected safely and in sufficient numbers
for the recipient. We sought to clarify the effects of
donor characteristics on stem cell donation and unre-
lated transplantation in our previous and current
works [14,15,27-29]. Future collaborations with Chi-
nese BM transplantation societies to further analyze
long-term transplantation outcomes and the impact
of recipient factors would greatly aid efforts to im-
prove transplantation in Chinese individuals.
In conclusion, our study has revealed that in Chi-
nese populations, HLA matching is an important fac-
tor influencing survival outcomes in MUD HSCT.
We have also shown that the HLA-C locus plays a sig-
nificant role in transplantation survival, necessitating
verification before transplantation. Inadequate cell
dose remains an important determinant of poor sur-
vival after MUDHSCT. Further studies investigating
the impact of donor characteristics and matching of
specific HLA loci on MUD HSCT outcomes in the
Chinese population may aid optimal donor selection
and ultimately improve outcomes in this population.ACKNOWLEDGMENTS
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